コンパニオンアニマル医薬品市場- 世界の産業規模、シェア、動向、機会、予測、適応症別、動物別、流通チャネル別、地域別、競合別、2019-2029年

コンパニオンアニマル医薬品の世界市場規模は2023年に145億2,000万米ドルとなり、2029年までのCAGRは8.25%で、予測期間中に着実な成長が予測されています。

世界のコンパニオンアニマル医薬品市場は、ペットの飼育数の増加、ペットの健康に対する意識の高まり、獣医学の進歩など、様々な要因が重なり、近年大きな成長を遂げています。犬、猫、馬を含むコンパニオンアニマルは、世界中の何百万人もの人々の生活に不可欠な役割を果たしており、彼らの健康上のニーズに合わせた医薬品に対する需要の高まりにつながっています。市場成長の主な促進要因のひとつは、ペットが家族の大切な一員とみなされるようになり、ペットの人間化が進んでいることです。このような認識の変化により、ペットの飼い主の間では、毛皮で覆われた仲間の健康を確保するための予防ヘルスケア対策や治療への投資意欲が高まっています。その結果、ノミやダニの治療薬から関節炎や糖尿病などの慢性疾患の治療薬まで、コンパニオンアニマル医薬品に対する需要が急増しています。獣医学の進歩と革新的な医薬製剤の利用可能性は、コンパニオンアニマルに利用可能な治療の選択肢を拡大しました。獣医師は現在、一般的な病気から複雑な病状に至るまで、ペットの様々な健康問題に対処するための幅広い医薬品や治療法を利用できます。さらに、経皮パッチやフレーバー薬などの新しいドラッグデリバリーシステムの開発により、ペットの飼い主が動物に薬を投与することが容易になり、コンプライアンスと治療成績が向上しました。

コンパニオンアニマルにおける疾患や障害の有病率の増加が、医薬品ソリューションの需要を促進しています。肥満、アレルギー、歯の問題などの症状はペットの間でより一般的になりつつあり、効果的な薬や治療法の必要性を高めています。さらに、獣医による治療や栄養状態の改善によりペットの寿命が延びるにつれて、関節炎や認知機能障害といった加齢に関連した疾患の発生率が増加しており、コンパニオンアニマル医薬品の需要をさらに押し上げています。地理的には、北米が世界のコンパニオンアニマル医薬品市場を独占しており、これはペットの飼育率の高さ、高度な獣医ヘルスケアインフラ、強力な規制の枠組みによるものです。欧州とアジア太平洋も、ペットの飼育率の増加、可処分所得の増加、ペットの健康とウェルネスに対する意識の高まりにより、大きな市場シェアを占めています。

有望な成長見通しとは裏腹に、コンパニオンアニマル医薬品市場はある課題に直面しています。これには、医薬品承認プロセスに関連する規制上のハードル、価格圧力、ハーブサプリメントやホリスティック治療などの代替療法との競合などがあります。さらに、現在進行中のCOVID-19パンデミックは市場力学に影響を与え、サプライチェーンの混乱や消費者行動の変化をもたらしています。

世界のコンパニオンアニマル医薬品市場の先行きは、動物医療の継続的な進歩、ペットの人間化動向の高まり、世界のペット飼育率の上昇に後押しされ、引き続き明るい見通しです。ペットの飼い主が毛皮で覆われた同伴者の健康と幸福を優先する傾向が続いているため、革新的な医薬品や治療法に対する需要が高まることが予想されます。製薬会社、獣医師、研究機関のコラボレーションは、市場のさらなる革新と拡大を促進し、最終的には世界中のコンパニオンアニマルとその飼い主に利益をもたらすと思われます。

主な市場促進要因

ペット飼育率の上昇

可処分所得の増加

主な市場課題

規制上のハードル

偽造品

主な市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のコンパニオンアニマル医薬品市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別（感染症、皮膚疾患、疼痛、整形外科疾患、行動疾患、その他）
  • 動物別（犬、猫、馬、その他）
  • 流通チャネル別（動物病院・診療所、薬局小売、その他）
  • 地域別
  • 企業別（2023）
• 市場マップ
  • 適応症別
  • 動物別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域のコンパニオンアニマル医薬品市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別
  • 動物別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州のコンパニオンアニマル医薬品市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別
  • 動物別
  • 流通チャネル別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米のコンパニオンアニマル医薬品市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別
  • 動物別
  • 流通チャネル別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米のコンパニオンアニマル医薬品市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別
  • 動物別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカのコンパニオンアニマル医薬品市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別
  • 動物別
  • 流通チャネル別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界のコンパニオンアニマル医薬品市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Zoetis Services LLC
• Merck & Co., Inc.
• Boehringer Ingelheim International GmbH
• Elanco Animal Health Incorporated
• Virbac Taiwan Co., Ltd.
• Vetoquinol S.A.
• Dechra Pharmaceuticals Limited
• Chanelle Pharma
• KyoritsuSeiyaku Corp

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Companion Animal Pharmaceuticals Market was valued at USD 14.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 8.25% through 2029. The global companion animal pharmaceuticals market has witnessed significant growth in recent years, driven by a combination of factors including increasing pet ownership, rising awareness about pet health, and advancements in veterinary medicine. Companion animals, including dogs, cats, and horses, play an integral role in the lives of millions of people worldwide, leading to a growing demand for pharmaceutical products tailored to their specific health needs. One of the key drivers of market growth is the increasing pet humanization trend, where pets are considered valued members of the family. This shift in perception has led to a greater willingness among pet owners to invest in preventive healthcare measures and treatments to ensure the well-being of their furry companions. As a result, there has been a surge in the demand for companion animal pharmaceuticals, ranging from flea and tick treatments to medications for chronic conditions like arthritis and diabetes. Advancements in veterinary medicine and the availability of innovative pharmaceutical formulations have expanded the treatment options available for companion animals. Veterinarians now have access to a wide array of drugs and therapies to address various health issues in pets, ranging from common ailments to complex medical conditions. Additionally, the development of novel drug delivery systems, such as transdermal patches and flavored medications, has made it easier for pet owners to administer medications to their animals, improving compliance and treatment outcomes.

The increasing prevalence of diseases and disorders in companion animals has fueled the demand for pharmaceutical solutions. Conditions such as obesity, allergies, and dental problems are becoming more prevalent among pets, driving the need for effective medications and therapies. Additionally, as pets live longer due to improved veterinary care and nutrition, there is a growing incidence of age-related ailments such as arthritis and cognitive dysfunction, further driving the demand for companion animal pharmaceuticals. Geographically, North America dominates the global companion animal pharmaceuticals market, attributed to the high pet ownership rates, advanced veterinary healthcare infrastructure, and strong regulatory framework. Europe and Asia-Pacific also hold significant market shares, driven by increasing pet adoption rates, rising disposable incomes, and growing awareness about pet health and wellness.

Despite the promising growth prospects, the companion animal pharmaceuticals market faces certain challenges. These include regulatory hurdles associated with drug approval processes, pricing pressures, and competition from alternative therapies such as herbal supplements and holistic treatments. Additionally, the ongoing COVID-19 pandemic has impacted the market dynamics, leading to disruptions in supply chains and changes in consumer behavior.

The outlook for the global companion animal pharmaceuticals market remains positive, fueled by continued advancements in veterinary medicine, growing pet humanization trends, and increasing pet ownership rates globally. As pet owners continue to prioritize the health and well-being of their furry companions, the demand for innovative pharmaceutical products and treatments is expected to rise. Collaborations between pharmaceutical companies, veterinarians, and research institutions are likely to drive further innovation and expansion in the market, ultimately benefiting companion animals and their owners worldwide.

Key Market Drivers

Rising Pet Ownership

The global companion animal pharmaceuticals market has experienced significant growth, with a primary driving force being the increasing number of pets worldwide. As people's love and attachment to their furry and feathered friends continue to grow, the demand for products and medications designed to enhance the health and well-being of companion animals has surged. This trend not only benefits pets and their owners but also presents a wealth of opportunities for pharmaceutical companies and the broader veterinary industry. Pet ownership has become more popular than ever, with pets increasingly viewed as cherished members of the family. This shift in perspective has led to greater investments in the health and well-being of companion animals. As people's lifestyles become busier, many are turning to pets for companionship and emotional support, especially in urban areas where social connections may be limited. The increasing recognition of the positive impact pets can have on human mental health has driven more individuals to adopt pets, leading to an expansion of the pet market. Society's changing attitudes have led to a reduction in the stigma associated with renting or living in smaller spaces with pets, making pet ownership more feasible for a wider range of people. Rising income levels in many parts of the world have allowed individuals to allocate more resources to their pets, including pharmaceutical products and healthcare.

The flourishing pet ownership trend has led to a surge in demand for companion animal pharmaceuticals, creating a flourishing global market. These pharmaceuticals encompass a wide range of products, including medications, vaccines, supplements, and various healthcare products tailored for pets. Pet owners are increasingly proactive in safeguarding their pets' health. Regular veterinary check-ups, vaccinations, and preventive treatments are becoming the norm, leading to greater pharmaceutical sales. The growing elderly pet population means an increased need for medications to manage age-related conditions, such as arthritis, diabetes, and heart disease. This trend has created opportunities for pharmaceutical companies to develop and market specialized medications. The development of medications and treatments specifically formulated for companion animals has become a significant driver of the market. These tailored solutions cater to the unique needs and preferences of pet owners. Companion animal pharmaceutical companies are constantly innovating, offering an ever-expanding range of products, from oral medications and topical treatments to advanced surgeries and specialty diets. Pet owners are investing more in veterinary services, which often involve the prescription and administration of pharmaceuticals. This trend fosters a symbiotic relationship between the veterinary industry and the pharmaceutical sector.

Increasing Disposable Income

The global companion animal pharmaceuticals market is experiencing a significant surge in growth, and one of the primary factors fueling this expansion is the increasing disposable income of pet owners. In recent years, pets have become more than just loyal companions; they are now considered part of the family. This shift in perspective has led to a substantial increase in pet healthcare spending, driving the companion animal pharmaceuticals market to new heights. In today's world, pets are treated as family members, receiving the same love and care that humans do. This shift in attitude, often referred to as the humanization of pets, has led to an upsurge in spending on pet healthcare. Pet owners are more willing to invest in the health and well-being of their furry friends, leading to a boom in the global companion animal pharmaceuticals market.

The primary driver behind the companion animal pharmaceuticals market's growth is the rise in disposable income of pet owners. With higher disposable incomes, individuals are more inclined to provide their pets with better healthcare, nutrition, and overall well-being. This upward trend is observed not only in developed countries but also in emerging markets, where disposable income is steadily on the rise. With increasing disposable income, pet owners can afford advanced healthcare services and treatments for their animals. This includes regular veterinary check-ups, vaccinations, and preventive care. As a result, pharmaceutical companies have witnessed a surge in the demand for companion animal pharmaceuticals to cater to these growing healthcare needs. Pet owners are now opting for premium and specialized pharmaceutical products to address specific health issues their animals may face. This includes medications, supplements, and even therapeutic diets. The increasing disposable income allows pet owners to invest in these high-quality products to ensure their pets' health and happiness. Higher disposable income has also enabled pet owners to become more aware and educated about their animals' health needs. They are willing to invest in knowledge, ensuring that they make informed decisions about their pets' healthcare. As a result, the demand for pharmaceuticals and healthcare products has surged.

Key Market Challenges

Regulatory Hurdles

One of the significant challenges for the companion animal pharmaceuticals market is the complex and evolving regulatory landscape. The industry must navigate through a multitude of regulations and guidelines that vary from one country to another. Different regulatory bodies in different regions may require varying levels of testing, safety assessments, and approvals for pet medications and vaccines. This can make it difficult for companies to efficiently develop and market products on a global scale. As the demand for companion animal pharmaceuticals continues to grow, the market has become increasingly competitive. Numerous companies are entering the market, leading to a broader range of products and services. While this competition can be beneficial for consumers and the overall industry, it can pose challenges for established companies seeking to maintain market share and profitability.

Counterfeit Products

The global companion animal pharmaceuticals market is plagued by the issue of counterfeit products. Counterfeit medications and vaccines can be harmful to pets and undermine trust in the industry. Consumers need to be vigilant and purchase products from reputable sources. Manufacturers and regulatory authorities must work together to combat the production and distribution of counterfeit pharmaceuticals. While awareness of the importance of pet healthcare has increased, there is still room for improvement. Many pet owners may not fully understand the need for regular veterinary visits, vaccinations, and the use of pharmaceuticals. This lack of awareness can limit the market's growth potential, as pet owners may not seek preventive healthcare for their animals until health issues become severe.

Ethical concerns regarding the testing of pharmaceutical products on animals can be a significant challenge in the industry. Many consumers and animal welfare organizations demand more ethical and humane approaches to testing. Companies must invest in alternative testing methods and clearly communicate their commitment to animal welfare to maintain public trust. The global supply chain, like many industries, has faced disruptions in recent times, with events like the COVID-19 pandemic affecting the production and distribution of pharmaceuticals. Supply chain disruptions can lead to product shortages, delayed deliveries, and increased costs. Companies in the companion animal pharmaceuticals market must have resilient supply chain strategies in place to mitigate these challenges.

Key Market Trends

Technological Advancements

The global companion animal pharmaceuticals market has experienced significant growth over the years, and one of the key drivers behind this expansion is the continuous wave of technological advancements. As technology evolves, it enhances the research, development, and delivery of innovative pharmaceutical solutions for our beloved pets. Technological advancements in genomics and biotechnology have revolutionized the development of companion animal pharmaceuticals. Researchers can now better understand the genetic makeup of animals, allowing for the creation of personalized medicines tailored to an individual pet's needs. This level of precision ensures safer and more effective treatments.

The integration of telemedicine and telehealth platforms has allowed pet owners to access veterinary consultations and prescription medications more conveniently. With the help of remote monitoring, digital health records, and telepharmacy services, pet owners can receive expert advice and order medications online, reducing the need for physical visits to the vet. Advancements in drug delivery systems have made administering medications to pets easier and more effective. Innovative methods such as transdermal patches, oral syrups, and extended-release formulations improve pet owners' ability to ensure their animals receive the right dose of medication at the right time. The use of big data analytics and artificial intelligence has enabled pharmaceutical companies and veterinarians to analyze vast amounts of data to improve treatment outcomes. AI can help in diagnosing diseases, predicting treatment responses, and identifying potential side effects, leading to more precise treatment options.

Continuous technological advancements provide opportunities for pharmaceutical companies to develop novel therapies and medications for companion animals. This, in turn, allows veterinarians to provide a higher standard of care for their patients. With the rise of online platforms and e-commerce, pharmaceutical companies can reach a broader customer base. Pet owners can easily order medications and pet health products, increasing convenience and accessibility. As technology bridges global divides, pharmaceutical companies have the chance to expand their reach beyond domestic markets. The global companion animal pharmaceuticals market presents immense growth potential for companies willing to enter new regions. Technological advancements often require collaboration between pharmaceutical companies, veterinary practices, and technology providers. These partnerships can lead to the development of innovative solutions and improve the overall ecosystem of companion animal healthcare.

Segmental Insights

Indication Insights

Based on indication, dermatologic diseases emerged as the fastest growing segment in the global market for companion animal pharmaceuticals in 2023. Dermatologic diseases encompass a wide range of conditions that affect the skin, hair, and nails of companion animals. These conditions can be caused by a variety of factors, including allergies, infections, parasites, autoimmune disorders, and more. Dermatologic issues are common in both dogs and cats, and they often manifest as itching, rashes, hair loss, and skin infections. These ailments can significantly reduce the quality of life for pets and can be distressing for their owners.

The high prevalence of dermatologic diseases in companion animals has led to an increased demand for pharmaceutical products specifically designed to treat these conditions. This demand has a significant impact on the global companion animal pharmaceuticals market in several ways. To meet the needs of pet owners, pharmaceutical companies have been investing in research and development to create more effective and convenient treatments for dermatologic diseases. These innovations include new topical creams, shampoos, oral medications, and injections, allowing veterinarians and pet owners a broader array of options for managing these conditions. The rising incidence of dermatologic diseases has prompted pharmaceutical companies to expand their product lines. This means a greater variety of treatment options are now available, catering to different types of skin issues, severity levels, and pet preferences. Dermatologic conditions often require professional diagnosis and management. This has led to an increase in demand for veterinary services specializing in dermatology, further driving the need for pharmaceutical products. These specialists can provide tailored treatment plans and recommendations for companion animals with skin issues.

Animal Insights

Based on animal, dogs segment is projected to experience rapid growth in Global Companion Animal Pharmaceuticals Market during the forecast period. The global pet population is on the rise, with dogs being one of the most popular choices as companions. The emotional bond between humans and their dogs has driven pet owners to prioritize the health and well-being of their four-legged family members. As a result, there is a growing demand for pharmaceutical products and services tailored to dogs' unique healthcare needs. With advancements in veterinary medicine and nutrition, dogs are living longer, healthier lives. However, like humans, older dogs are prone to various health issues, such as arthritis, diabetes, and cardiovascular problems. This aging demographic of dogs has led to an increased need for specialized pharmaceuticals to address age-related ailments, ultimately contributing to the growth of the companion animal pharmaceuticals market.

The concept of preventive healthcare for pets has gained momentum in recent years. Dog owners are increasingly focused on keeping their pets healthy and preventing diseases rather than just treating them when they occur. This trend has led to the expansion of product lines that include vaccines, flea and tick preventatives, and nutritional supplements, all of which boost the companion animal pharmaceuticals market. As dogs continue to be considered integral members of the family, there has been a rise in the humanization of pets. Dog owners are more willing to invest in their pets' well-being, which includes spending on higher-quality foods, pharmaceuticals, and veterinary services. This shift in perspective has led to increased expenditures on companion animal pharmaceuticals.

Regional Insights

Based on region, North America emerged as the dominant region in the Global Companion Animal Pharmaceuticals Market in 2023, holding the largest market share in terms of value. One of the primary factors fueling the growth of the companion animal pharmaceuticals market in North America is the increasing trend of pet ownership. North America, particularly the United States and Canada, has seen a significant rise in the number of households that have pets, including dogs, cats, and other companion animals. These pets have become cherished members of the family, leading owners to invest in their well-being and healthcare. With more pets in homes, there is a higher demand for pharmaceutical products such as vaccines, medications, and supplements to maintain the health and longevity of these beloved animals. This surge in pet ownership is creating a robust market for pharmaceutical companies specializing in companion animal health.

North American pet owners are becoming increasingly aware of the importance of preventive healthcare for their animals. This awareness has translated into greater willingness to spend on veterinary care and pharmaceutical products. Regular check-ups, vaccinations, and treatments for common health issues have become the norm, further driving the demand for companion animal pharmaceuticals. Veterinarians in North America play a pivotal role in educating pet owners about the benefits of preventive care. They recommend and prescribe pharmaceutical products that cater to specific health needs, making them essential stakeholders in the companion animal pharmaceuticals market. As the awareness of pet healthcare continues to grow, the market for such products in North America is set to expand even further.

Key Market Players

Zoetis Services LLC

Merck & Co., Inc.

Boehringer Ingelheim International GmbH

Elanco Animal Health Incorporated

Virbac Taiwan Co., Ltd.

Vetoquinol S.A.

Dechra Pharmaceuticals Limited

Chanelle Pharma

KyoritsuSeiyaku Corp

Report Scope:

In this report, the Global Companion Animal Pharmaceuticals Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Companion Animal Pharmaceuticals Market, By Indication:

Infectious diseases Dermatologic diseases Pain Orthopedic diseases Behavioural diseases Other

Companion Animal Pharmaceuticals Market, By Animal:

Dogs Cats Horses Other

Companion Animal Pharmaceuticals Market, By Distribution Channel:

Veterinary hospitals and clinics Retail pharmacies Others

Companion Animal Pharmaceuticals Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Companion Animal Pharmaceuticals Market.

Available Customizations:

Global Companion Animal Pharmaceuticals Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Companion Animal Pharmaceuticals Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Indication (Infectious Diseases, Dermatologic Diseases, Pain, Orthopedic Diseases, Behavioral Diseases, Other)
  • 4.2.2. By Animal (Dogs, Cats, Horses, Other)
  • 4.2.3. By Distribution Channel (Veterinary Hospitals and Clinics, Retail Pharmacies, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2023)
• 4.3. Market Map
  • 4.3.1. By Indication
  • 4.3.2. By Animal
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Companion Animal Pharmaceuticals Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication
  • 5.2.2. By Animal
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Companion Animal Pharmaceuticals Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Indication
      • 5.3.1.2.2. By Animal
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Companion Animal Pharmaceuticals Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Indication
      • 5.3.2.2.2. By Animal
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Companion Animal Pharmaceuticals Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Indication
      • 5.3.3.2.2. By Animal
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Companion Animal Pharmaceuticals Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Indication
      • 5.3.4.2.2. By Animal
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Companion Animal Pharmaceuticals Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Indication
      • 5.3.5.2.2. By Animal
      • 5.3.5.2.3. By Distribution Channel

6. Europe Companion Animal Pharmaceuticals Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Animal
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Companion Animal Pharmaceuticals Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Animal
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Companion Animal Pharmaceuticals Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Animal
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Companion Animal Pharmaceuticals Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Animal
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Companion Animal Pharmaceuticals Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Indication
      • 6.3.4.2.2. By Animal
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Companion Animal Pharmaceuticals Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Indication
      • 6.3.5.2.2. By Animal
      • 6.3.5.2.3. By Distribution Channel

7. North America Companion Animal Pharmaceuticals Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Animal
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Companion Animal Pharmaceuticals Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Animal
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Companion Animal Pharmaceuticals Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Animal
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Companion Animal Pharmaceuticals Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Animal
      • 7.3.3.2.3. By Distribution Channel

8. South America Companion Animal Pharmaceuticals Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Animal
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Companion Animal Pharmaceuticals Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Animal
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Companion Animal Pharmaceuticals Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Animal
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Companion Animal Pharmaceuticals Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Animal
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Companion Animal Pharmaceuticals Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Animal
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Companion Animal Pharmaceuticals Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Animal
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Companion Animal Pharmaceuticals Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Animal
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Companion Animal Pharmaceuticals Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Animal
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Companion Animal Pharmaceuticals Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Zoetis Services LLC
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Product & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Merck & Co., Inc.
• 14.3. Boehringer Ingelheim International GmbH
• 14.4. Elanco Animal Health Incorporated
• 14.5. Virbac Taiwan Co., Ltd.
• 14.6. Vetoquinol S.A.
• 14.7. Dechra Pharmaceuticals Limited
• 14.8. Chanelle Pharma
• 14.9. KyoritsuSeiyaku Corp

15. Strategic Recommendations

16. About Us & Disclaimer